BidaskClub lowered shares of Collegium Pharmaceutical (NASDAQ:COLL) from a hold rating to a sell rating in a research note published on Monday, BidAskClub reports.

A number of other research firms have also recently commented on COLL. Zacks Investment Research raised shares of Collegium Pharmaceutical from a sell rating to a hold rating in a research note on Tuesday, March 5th. Cantor Fitzgerald set a $35.00 target price on shares of Collegium Pharmaceutical and gave the stock a buy rating in a research note on Friday, March 8th. ValuEngine raised shares of Collegium Pharmaceutical from a sell rating to a hold rating in a research note on Thursday, February 28th. SunTrust Banks assumed coverage on shares of Collegium Pharmaceutical in a research note on Tuesday, March 19th. They set a buy rating and a $22.00 target price for the company. Finally, Janney Montgomery Scott assumed coverage on shares of Collegium Pharmaceutical in a research note on Friday, April 12th. They set a buy rating and a $29.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of $27.29.

COLL opened at $11.67 on Monday. Collegium Pharmaceutical has a fifty-two week low of $11.53 and a fifty-two week high of $28.91. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.24 and a quick ratio of 1.19.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.01. The company had revenue of $74.52 million during the quarter, compared to analysts’ expectations of $70.10 million. Collegium Pharmaceutical had a negative net margin of 10.36% and a negative return on equity of 30.87%. Research analysts anticipate that Collegium Pharmaceutical will post -0.42 EPS for the current fiscal year.

In other news, Director Michael Thomas Heffernan sold 25,000 shares of the business’s stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $12.84, for a total transaction of $321,000.00. Following the completion of the sale, the director now owns 188,586 shares of the company’s stock, valued at $2,421,444.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 75,000 shares of company stock valued at $1,127,500 in the last three months. Corporate insiders own 8.08% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Morgan Stanley boosted its position in Collegium Pharmaceutical by 20.1% during the third quarter. Morgan Stanley now owns 1,056,133 shares of the specialty pharmaceutical company’s stock worth $15,566,000 after acquiring an additional 176,577 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its position in Collegium Pharmaceutical by 4.8% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 14,359 shares of the specialty pharmaceutical company’s stock worth $247,000 after acquiring an additional 655 shares during the last quarter. Monarch Partners Asset Management LLC boosted its position in Collegium Pharmaceutical by 19.2% during the fourth quarter. Monarch Partners Asset Management LLC now owns 33,770 shares of the specialty pharmaceutical company’s stock worth $580,000 after acquiring an additional 5,430 shares during the last quarter. MetLife Investment Advisors LLC acquired a new position in Collegium Pharmaceutical during the third quarter worth about $339,000. Finally, Meeder Asset Management Inc. boosted its position in Collegium Pharmaceutical by 644.8% during the fourth quarter. Meeder Asset Management Inc. now owns 3,672 shares of the specialty pharmaceutical company’s stock worth $62,000 after acquiring an additional 3,179 shares during the last quarter. Hedge funds and other institutional investors own 94.41% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Recommended Story: Consumer Price Index (CPI)

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.